TW200503707A - Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease - Google Patents

Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease

Info

Publication number
TW200503707A
TW200503707A TW092134949A TW92134949A TW200503707A TW 200503707 A TW200503707 A TW 200503707A TW 092134949 A TW092134949 A TW 092134949A TW 92134949 A TW92134949 A TW 92134949A TW 200503707 A TW200503707 A TW 200503707A
Authority
TW
Taiwan
Prior art keywords
alzheimer
intestinal
disease
prevention
application
Prior art date
Application number
TW092134949A
Other languages
English (en)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert Heuer
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TW200503707A publication Critical patent/TW200503707A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TW092134949A 2002-12-12 2003-12-11 Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease TW200503707A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
TW200503707A true TW200503707A (en) 2005-02-01

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092134949A TW200503707A (en) 2002-12-12 2003-12-11 Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease

Country Status (22)

Country Link
EP (1) EP1572174A1 (zh)
JP (1) JP2006514063A (zh)
KR (1) KR20050084250A (zh)
CN (1) CN1726016A (zh)
AR (1) AR042354A1 (zh)
AU (1) AU2003296802A1 (zh)
BR (1) BR0317280A (zh)
CA (1) CA2507945A1 (zh)
CO (1) CO5700712A2 (zh)
FR (1) FR2848452B1 (zh)
HR (1) HRP20050534A2 (zh)
MA (1) MA27500A1 (zh)
MX (1) MXPA05005556A (zh)
NO (1) NO20053341L (zh)
NZ (1) NZ540496A (zh)
PE (1) PE20040770A1 (zh)
PL (1) PL377110A1 (zh)
RS (1) RS20050420A (zh)
RU (1) RU2005121909A (zh)
TW (1) TW200503707A (zh)
WO (1) WO2004062652A1 (zh)
ZA (1) ZA200504656B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2937085B1 (en) * 2007-05-22 2019-07-10 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) * 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
AU3585397A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
KR20050084250A (ko) 2005-08-26
CA2507945A1 (fr) 2004-07-29
CO5700712A2 (es) 2006-11-30
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
BR0317280A (pt) 2005-11-08
PL377110A1 (pl) 2006-01-23
AU2003296802A1 (en) 2004-08-10
JP2006514063A (ja) 2006-04-27
ZA200504656B (en) 2006-08-30
RU2005121909A (ru) 2006-01-20
NO20053341D0 (no) 2005-07-08
PE20040770A1 (es) 2004-12-10
FR2848452B1 (fr) 2007-04-06
MXPA05005556A (es) 2005-07-26
RS20050420A (en) 2007-04-10
EP1572174A1 (fr) 2005-09-14
MA27500A1 (fr) 2005-08-01
AR042354A1 (es) 2005-06-15
CN1726016A (zh) 2006-01-25
HRP20050534A2 (en) 2006-11-30
WO2004062652A1 (fr) 2004-07-29
FR2848452A1 (fr) 2004-06-18

Similar Documents

Publication Publication Date Title
GB0223040D0 (en) Therapeutic compounds
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
AP2004002951A0 (en) "Combination of Eplerenone and an HMG CoA Reductase Inhibitor".
EP1638950A4 (en) CYCLOHEXYLGLYCIN DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2004103960A3 (en) Compounds and uses thereof
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
HK1073313A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL174536A0 (en) Therapeutic treatment
MY133332A (en) Pyrrolidone derivatives as maob inhibitors
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
EP1604664A4 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
MA27500A1 (fr) Prevention et traitement de la maladie d'alzheimer
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
TW200714280A (en) Novel method of treating hyperlipidemia
UA85187C2 (en) 2-aminobenzoyl derivatives
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
DE50202331D1 (de) Verwendung eines phosphatadsorbers gegen gefässerkrankungen
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
WO2008060837A3 (en) Methods and compositions for the treatment of cancer